Sep 11, 2012, 08.20 AM IST
Medical equipment maker Opto Circuits today said it has received approval from India's health regulator for a medical device for heart patients, following which it has launched the product in the market.
Opto Eurocor Healthcare, a subsidiary of Opto Circuits (India), launched Sirolimus Drug Eluting Stent (DES), E-Magic Plus on receipt of Drug Controller General of India (DCGI) licence to sell and market the product in India, Opto Circuits said in a statement.
A stent is a wire metal mesh tube that is used to open a blocked artery during an angioplasty.
"E-Magic Plus has been developed indigenously in India and with the DCGI mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East," Opto Circuits (India) Ltd Chairman & Managing Director Vinod Ramnani said.
Sirolimus DES market is estimated to be worth Rs 800 crore in India, he added.
The DES market has two major drug categories: Sirolimus and Paclitaxel. In India, Sirolimus-based angioplasty devices have a more than 90% market share, the company said. "Opto Eurocor Healthcare Ltd will launch E-Magic Plus in the European and Latin-American market after receiving the
Shares of Opto Circuits today closed at Rs 129.60 on the BSE, down 0.96% from previous closing.
Opto Circuits stock price
On December 10, 2013, Opto Circuits India closed at Rs 22.30, down Rs 0.3, or 1.33 percent. The 52-week high of the share was Rs 113.90 and the 52-week low was Rs 17.80.
The company's trailing 12-month (TTM) EPS was at Rs 6.24 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 3.57. The latest book value of the company is Rs 60.01 per share. At current value, the price-to-book value of the company is 0.37.
Action in Opto Circuits India
Video of the day
Dec 10 2013, 11:21
- in FII View
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.